Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 21:55:59 GMT 2025
by
admin
on
Tue Apr 01 21:55:59 GMT 2025
|
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
HR6E2AWX74
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Q96SW2
Created by
admin on Tue Apr 01 21:55:59 GMT 2025 , Edited by admin on Tue Apr 01 21:55:59 GMT 2025
|
PRIMARY | |||
|
HR6E2AWX74
Created by
admin on Tue Apr 01 21:55:59 GMT 2025 , Edited by admin on Tue Apr 01 21:55:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
LIGAND->TARGET |
CRBN ubiquitination studies in the transfected HEK293T cells resulted in the following potencies: CC-220 IC50 = 0.19 ?M; lenalidomide IC50 = 12.9 ?M; and pomalidomide IC50 = 21.6 ?M.
BINDING
IC50
|
||
|
|
INHIBITOR -> TARGET | |||
|
|
MODULATOR->TARGET |
|
||
|
|
INDUCER -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
|
||
|
LIGAND->TARGET |
IN-VITRO
|
||
|
MODULATOR->TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
|
||
|
LIGAND->TARGET |
|
||
|
MODULATOR->TARGET |
|
||
|
LIGAND->TARGET |
Kd
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|